The PhenoImager Solution

Spatial Signatures at Scale

We’ve rebranded some of our products, learn more ›

CODEX is now PhenoCycler
Phenoptics is now Phenolmager

PhenoImager – Rapid, accurate spatial phenotyping

Unraveling the complex and dynamic tumor microenvironment requires multiplex immunofluorescence imaging to assess a variety of tumor and immunologic biomarkers. Spatial Phenotypic Signatures are a new class of highly predictive biomarker which measure the interactions and cellular densities of tumor and immune cells that compose the tumor microenvironment.

Multiplex imaging utilizing novel biomarkers can reveal the spatial relationships between tumor and immune cells, leading to the discovery of spatial phenotypic signatures while preserving the architectural features of the tumor microenvironment.

Our PhenoImager® Instruments, powered by patented Multispectral Imaging (MSI) Technology, are the fastest quantitative digital pathology imaging platforms enabling rapid and accurate spatial phenotyping at scale.

Pave the path for spatial phenotypic signatures with your team using the PhenoImager.

Benefits

icon-speed

Fast

Fastest Spatial Phenotyping Imagers in the world
icon-data

Accurate

Patented MSI Technology Enables Quantitative Spatial Phenotyping
icon-workflow

Integrated

Integrated Multiplex Immunofluorescence Imaging Solution Optimized from Sample to Result
icon-optimization

Efficient

Get More Data by Multiplexing While Saving Precious Samples

Case Studies

phenoimager-casestudy1
First Multi-Institutional Analytical Demonstration of a Spatial Biology Workflow
The MITRE study, published in the Journal for ImmunoTherapy of Cancer, established the high reproducibility and robustness of Akoya Biosciences’ PhenoImager mutliplex immnuofluorescence platform for spatial phenotyping in clinical research.

Top immuno-oncology and pathology experts from five institutions collaborated with Akoya to conduct the MITRE study, including Johns Hopkins University School of Medicine, Yale University School of Medicine, Earle A. Chiles Research Institute, The University of Texas MD Anderson Cancer Center, and Bristol Myers Squibb.
Spatial Biomarkers in Immuno-Oncology: Recent Developments and Future Directions
In this four-part webinar series, researchers discuss pioneering new strategies representing significant milestones that advance Spatial Biology into the realm of patient phenotyping and improving immunotherapy outcomes in the future. Hear from our expert panel on recent developments that establishes the vital role of Spatial Biomarkers in setting the future directions in achieving Precision Immuno-Oncology.
Image of a normal brain and a brain with advanced chronic traumatic encephalopathy.
Contact sports and Chronic Traumatic Encephalopathy (CTE)
Learn how researchers used multiplex immunofluorescence to study various Tau isoforms and identify early pathological changes in CTE

Imaging Gallery

Technology

MSI-Technology-Image

Watch this video to learn about how the PhenoImager instruments use a patented Multispectral Imaging (MSI) Technology and spectral unmixing to isolate autofluorescence and biomarkers of interest regardless of their intensity or any spectral overlap into separate channels, providing accurate and quantitative data for spatial phenotyping applications.

Workflow

Related Publications

Spatially organized multicellular immune hubs in human colorectal cancer
2021 Aug 26
Researchers at The Broad Institute apply multiplex immunofluorescence imaging to show how immune cell hubs are organized in structured cell neighborhoods within human colorectal cancers.
Immune infiltrate dynamics and response to chemotherapy in breast cancer
2021 Aug 12
West German Study Group researchers utilize multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC).
Role of tertiary lymphoid structures (TLSs) in response to immunotherapy
2021 Aug 20
University of Bordeaux team applies multiplex immunofluorescence imaging to identify mature TLSs within several solid tumors and show their association with better outcomes for cancer patients treated with immunotherapy.

Get in touch with us

Technical Support

An Akoya technical expert is happy to help, contact us today!

Contact a Representative

We are happy to answer any questions you have about our platforms, technology and services.